Orgenesis Inc.
Unlocking the Potential of Cell and Gene Therapy for All (NASDAQ: ORGS)
65 employees · est. 2012 · Germantown, United States
ViaCyte
Regenerating Health: Transforming the lives of patients with insulin-requiring diabetes
35 employees · est. 1999 · San Diego, United States
ViaCyte is the older company (2012 vs 1999); Orgenesis Inc. is the larger of the two.
Side-by-Side Comparison
| Metric | Orgenesis Inc. | ViaCyte |
|---|---|---|
| Founded | ||
| Founded | 2012 | 1999 older |
| Headquarters | ||
| Headquarters | Germantown, United States | San Diego, United States |
| Employees | ||
| Employees | 65 larger | 35 |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biotechnology, Health Care, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Grant | Series D |
| Total Funding | ||
| Total Funding | $69.12M | $235.55M |
| Funding Rounds | ||
| Funding Rounds | 9 | 15 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Biotech, Cell Therapy, Gene Therapy, POCare Network, Decentralized Production, Diabetes Treatment, Autologous Insulin Producing (AIP) Cell Transplantation, Beta Cell Replacement, Pancreas Islet Transplantation, Clinical Trials, FDA Guidelines, Molecular And Cellular Approach, Global Biotech Company, Organ Regeneration, Insulin-dependent Diabetes Mellitus | Regenerative Medicine, Cell Therapy, Diabetes Treatment, Stem Cell Therapy, Pancreatic Islet Progenitor Cells, Type 1 Diabetes, Insulin Replacement Therapy, Clinical Evaluation, Immuno-evasive Therapy, Collaborative Partnerships, CRISPR Therapeutics, W.L. Gore & Associates, Chronic Disease Management, Medical Device Innovation, Cell Differentiation |
| Website | ||
| Website | orgenesis.com | viacyte.com |
About Orgenesis Inc.
Orgenesis Inc. is a leading global biotech company committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2008. The company's slogan, "Unlocking the Potential of Cell and Gene Therapy for All (NASDAQ: ORGS)", reflects its core mission. In 2020, Orgenesis initiated...
About ViaCyte
ViaCyte is a biotechnology startup from the United States, focused on developing revolutionary cell replacement therapies for long-term diabetes treatment, aiming to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates a...
We will tell you when either one moves
BounceWatch watches Orgenesis Inc. and ViaCyte for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Orgenesis Inc. and ViaCyte — by email.
Frequently Asked Questions
Compare Orgenesis Inc. with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Orgenesis Inc. on 12 Sep 2024, and ViaCyte on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.